Altre lingue Pulmonx Corporation

Azioni

LUNG

US7458481014

Tempo reale stimato Cboe BZX Altri mercati azionari 21:15:28 19/04/2024			Variaz. 5gg	Var. 1 gen.
7,41 ^USD	-1,20%		-6,34%	-42,04%

26/02	Pulmonx Corporation annuncia il trattamento del primo paziente con il Sistema Aeriseal nello studio pivotale Convert II	CI
23/02	Le azioni Pulmonx scendono dopo il declassamento di Wells Fargo	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024	10/04
Pulmonx Appoints Mehul Joshi as Chief Financial Officer	02/04
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer	02/04
Pulmonx Corporation Announces Chief Financial Officer Changes, Effective April 3, 2024	02/04
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	15/03
Pulmonx Announces Treatment of the First Patient with the AeriSeal System in CONVERT II Pivotal Trial	27/02
Pulmonx kondigt behandeling aan van de eerste patiënt met het AeriSeal®-systeem in de CONVERT II-studie	27/02
Pulmonx meldet Behandlung des ersten Patienten mit dem AeriSeal®-System in der CONVERT-II-Zulassungsstudie	27/02
Pulmonx annonce le traitement du premier patient par système AeriSeal® dans l'essai pivot CONVERT II	27/02
Pulmonx anuncia el tratamiento del primer paciente con el sistema AeriSeal® en el ensayo pivotal CONVERT II	27/02
Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial	26/02
Pulmonx Corporation Announces Treatment of the First Patient with the Aeriseal System in Convert II Pivotal Trial	26/02
North American Morning Briefing : Traders Await -2-	26/02
Pulmonx Shares Fall After Wells Fargo Downgrade	23/02
Earnings Flash (LUNG) PULMONX CORPORATION Reports Q4 Revenue $19.3M, vs. Street Est of $18.2M	21/02
Pulmonx Corporation Provides Earnings Guidance for the Full Year 2024	21/02
Pulmonx Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21/02
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer	21/02
Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results	21/02
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer	21/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Pulmonx Corporation

Azioni

LUNG

US7458481014

Altre lingue

Filtri